Biotechnology stocks have plummeted since pandemic peaks and the majority of investment trusts that focus on the sector have fallen, unsurprisingly, to discounts. However, analysts at Stifel have said this provides a “fertile environment for active funds to pick through the wreckage” and the trusts themselves are worth another look. Meanwhile, Berenberg say the healthcare peers also should not be ignored.
There are seven trusts in the Association of Investment Companies (AIC) biotechnology and healthcare sector. Of these just two are trading on premiums, BB Healthcare and Syncona, which are on 1.7% and 13.5% premiums respectively. The remaining five range from discounts of 1.2% (Biotech Growth) to as high as 14.6% (RTW Venture). These discounts are understandable given Refinitiv data, reported by the Financial Times today (10 February), shows 83% of recent biotech listings are now trading well below their IPO price. "The sector was in vogue following the discovery of the Covid-19 vacci...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
